SCHEMBL6424410

SCHEMBL6424410

COC(=O)c1cscc1C=CCO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 5/20 0.33
GLA P06280 2/20 0.33
BACE1 P56817 1/20 0.33
GAA P10253 2/20 0.33
TSHR P16473 2/20 0.33
LMNA P02545 2/20 0.33
FABP6 P51161 1/20 0.32
PTGS2 P35354 1/20 0.32
ALDH1A1 P00352 3/20 0.32
HSD17B10 Q99714 2/20 0.32
CFTR P13569 1/20 0.32
CHEK1 O14757 1/20 0.31
MET P08581 1/20 0.31
GSK3B P49841 1/20 0.31
LIMK1 P53667 1/20 0.31
DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6424408 1.00 MAPK8 (0.35) MAPK8MAPK9MAPK10KMT2AKDM4E
SCHEMBL6421451 0.79 KDM4E (0.33) MAPK8MAPK9MAPK10KDM4EGLA
SCHEMBL6421448 0.79 KDM4E (0.33) MAPK8MAPK9MAPK10KDM4EGLA
SCHEMBL3723136 0.78 ALDH1A1 (0.40) MAPK8MAPK9MAPK10KDM4ETSHR
SCHEMBL10371764 0.75 BACE1 (0.56) KMT2AKDM4EGLABACE1GAA
SCHEMBL10371766 0.75 BACE1 (0.56) KMT2AKDM4EGLABACE1GAA
SCHEMBL68934 0.74 TSHR (0.46) MAPK8MAPK9MAPK10KDM4EGLA
SCHEMBL6425897 0.73 NPSR1 (0.37) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL6425899 0.73 NPSR1 (0.37) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL6420720 0.71 ABL1 (0.49) KMT2AKDM4EGLALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 MAPK8 1493/4885MAPK9 1948/4885MAPK10 657/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 MAPK8 2101/4885MAPK9 2789/4885MAPK10 960/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 MAPK8 2140/4885MAPK9 2747/4885MAPK10 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.